Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.70 |
| ▸ | NPC1 | O15118 | 3/20 | 0.70 |
| ▸ | IDO1 | P14902 | 2/20 | 0.60 |
| ▸ | TDO2 | P48775 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | HPGD | P15428 | 2/20 | 0.57 |
| ▸ | HTT | P42858 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | PLG | P00747 | 2/20 | 0.48 |
| ▸ | KLK1 | P06870 | 2/20 | 0.48 |
| ▸ | KLK6 | Q92876 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.46 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31320843 | 1.00 | RAB9A (0.70) | RAB9ANPC1IDO1TDO2KDM4E | |
| SCHEMBL4187193 | 0.85 | RAB9A (0.62) | RAB9ANPC1IDO1TDO2KDM4E | |
| SCHEMBL4225391 | 0.85 | RAB9A (0.70) | RAB9ANPC1IDO1TDO2KDM4E | |
| SCHEMBL9274995 | 0.83 | RAB9A (0.53) | RAB9ANPC1IDO1TDO2MAPT | |
| SCHEMBL3174922 | 0.82 | NPC1 (0.66) | RAB9ANPC1IDO1TDO2KDM4E | |
| SCHEMBL8876085 | 0.82 | RAB9A (0.66) | RAB9ANPC1IDO1TDO2KDM4E | |
| SCHEMBL9639259 | 0.81 | HSP90AB1 (0.69) | RAB9ANPC1IDO1TDO2KDM4E | |
| SCHEMBL21591498 | 0.80 | MAPT (0.49) | RAB9ANPC1IDO1TDO2KDM4E | |
| SCHEMBL9700386 | 0.80 | RAB9A (0.46) | RAB9ANPC1IDO1TDO2KDM4E | |
| SCHEMBL31085015 | 0.80 | MAPT (0.49) | RAB9ANPC1IDO1TDO2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5877210-A | CONTROLLING IMMUNE RESPONSE | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-03-02 | — | — | US | claimed |
| US-5583242-A | VANADYL COMPLEXES | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-12-10 | — | — | US | claimed |
| US-5565491-A | FOR TREATMENT OF DISEASES MARKED BY MALIGNANT PROLIFERATION OF B CELLS, SUCH AS LEUKEMIA AND LYMPHOMAS; ANTICARCINOGENIC AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-10-15 | — | — | US | claimed |
| US-20230241078-A1 | Vanadyl and vanadate for use in reducing stress-induced metabolic derangement | CFM PHARMA HOLDING B.V. (NL) | 2023-08-03 | — | — | US | disclosed |
| US-20200246352-A1 | Vanadyl and vanadate for use in reducing stress-induced metabolic derangement | CFM PHARMA HOLDING B.V. (NL) | 2020-08-06 | — | — | US | disclosed |
| EP-3684352-A1 | VANADYL AND VANADATE FOR USE IN REDUCING STRESS -INDUCED METABOLIC DERANGEMENT | CFM Pharma Holding BV (NL) | 2020-07-29 | — | — | EP | disclosed |
| WO-2019059770-A1 | VANADYL AND VANADATE FOR USE IN REDUCING STRESS -INDUCED METABOLIC DERANGEMENT | CFM PHARMA HOLDING B.V. (NL) | 2019-03-28 | — | — | WO | disclosed |
| US-8883935-B2 | High refractive index composition | BATTELLE MEMORIAL INSTITUTE (US) | 2014-11-11 | — | — | US | disclosed |
| US-8883935-B2 | High refractive index composition | BATTELLE MEMORIAL INSTITUTE (US) | 2014-11-11 | — | — | US | disclosed |
| US-20130046054-A1 | HIGH REFRACTIVE INDEX COMPOSITION | BATTELLE MEMORIAL INSTITUTE (US) | 2013-02-21 | — | — | US | disclosed |
| US-20130046054-A1 | HIGH REFRACTIVE INDEX COMPOSITION | BATTELLE MEMORIAL INSTITUTE (US) | 2013-02-21 | — | — | US | disclosed |
| US-7851640-B2 | Catalytic enantioselective synthesis of flavanones and chromanones | NORTHWESTERN UNIVERSITY (US) | 2010-12-14 | — | — | US | disclosed |
| US-20090259055-A1 | Catalytic enantioselective synthesis of flavanones and chromanones | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-10-15 | — | — | US | disclosed |
| US-5877210-A | CONTROLLING IMMUNE RESPONSE | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-03-02 | — | — | US | disclosed |
| US-5846998-A | Use of phosphotyrosine phosphatase inhibitors or phosphotyrosine kinase activators for controlling cellular proliferation | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-12-08 | — | — | US | disclosed |
| US-5693627-A | TREATING DISEASES SUCH AS LEUKEMIAS AND LYMPHOMAS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1997-12-02 | — | — | US | disclosed |
| US-5583242-A | VANADYL COMPLEXES | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-12-10 | — | — | US | disclosed |
| US-5565491-A | FOR TREATMENT OF DISEASES MARKED BY MALIGNANT PROLIFERATION OF B CELLS, SUCH AS LEUKEMIA AND LYMPHOMAS; ANTICARCINOGENIC AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-10-15 | — | — | US | disclosed |
| EP-0735880-A1 | USE OF VANADIUM MOLYBDENUM OR TUNGSTEN COMPLEXES FOR CONTROLLING CELLULAR PROLIFERATION | Bristol-Myers Squibb Company (US) | 1996-10-09 | — | — | EP | disclosed |
| WO-1995020390-A1 | USE OF VANADIUM MOLYBDENUM OR TUNGSTEN COMPLEXES FOR CONTROLLING CELLULAR PROLIFERATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090259055-A1 | Catalytic enantioselective synthesis of flavanones and chromanones | RNGTT, CDK20, TBXAS1 | RAB9A 3477/4885NPC1 4587/4885IDO1 1521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.